On August 2, 2023 (Notice Date), Dr. Kenneth Hillan, Chief Therapeutics Officer of 23andMe Holding Co. (company), notified the company of his decision to retire. In connection with such notice, Dr. Hillan stepped down from his position and ceased to serve as the Company?s Chief Therapeutics Officer, effective as of August 8, 2023.

Dr. Hillan will continue to be employed by the Company through and until his retirement on February 8, 2024 (Retirement date) or such earlier date as determined by the Board (Transition Period), during which time Dr. Hillan will assist in the transition of his responsibilities and duties.